Skip to main content
. 2020 Sep 30;6(3):270–274. doi: 10.5114/ceh.2020.99528

Table 1.

Baseline characteristics of patients treated with pemafibrate

Variables N= 38
Age (years), mean ±SE 57.1 ±2.2
Gender (male), n (%) 22 (58)
Currently using tobacco, n (%) 2 (5)
Complications treated with medications, n (%)
Hypertension 16 (42)
Gastroesophageal reflux disease 13 (34)
Hyperuricemia 3 (8)
Diabetes mellitus 0 (0)
Combination use, n (%)
Statins 27 (71)
Ezetimibe 10 (26)
Angiotensin II receptor blockers 11 (29)
Eicosapentaenoic acid/docosahexaenoic acid 1 (3)